EU's CHMP recommends Amgen's Prolia for two indications
21 December 2009
Katie McQue
The EU's
CHMP has endorsed
Amgen's Prolia (denosumab) for the treatment of osteoporosis in postmenopausal women at risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Once approved,...
Please Login to read the full article.